MENLO PARK, Calif.--(BUSINESS WIRE)--Summit Therapeutics Inc. (NASDAQ: SMMT) (“Summit,” “we,” or the “Company”) today announced that Manmeet S. Soni has been appointed as the Company’s Chief Operating Officer, effective immediately. Mr. Soni will remain a member of the Company’s Board of Directors.

加利福尼亚州门洛帕克-（商业线）-Summit Therapeutics Inc.（纳斯达克股票代码：SMMT）（“Summit”，“we”或“公司”）今天宣布Manmeet S.Soni已被任命为该公司的首席运营官，立即生效。Soni先生将继续担任本公司董事会成员。

“Manmeet Soni has few peers in this industry, and his track record speaks for itself,” stated Dr. Maky Zanganeh, Chief Executive Officer and President of Summit. “With our focus on bringing to life our mission to improve the quality and potential duration of lives of patients facing serious unmet medical needs via our investigational novel bispecific antibody, ivonescimab,* we are thrilled to add an accomplished, world-class biopharmaceutical executive to our leadership team.

首席执行官兼峰会主席Maky Zanganeh博士说：“Manmeet Soni在这个行业几乎没有同行，他的记录自言自语。”。“通过我们的研究性新型双特异性抗体ivonescimab，我们专注于为生活带来我们的使命，以提高面临严重未满足医疗需求的患者的生活质量和潜在持续时间，*我们很高兴为我们的领导团队增加一位经验丰富的世界级生物制药执行官。

Manmeet will bring substantial value to our organization as we engage in our next steps, including the continued expansion of our organization and the potential commercialization of ivonescimab.”.

当我们参与下一步工作时，Manmeet将为我们的组织带来实质性价值，包括我们组织的持续扩张和ivonescimab的潜在商业化“。

“Manmeet provides excellent stewardship and guidance as a member of our Board, but we are incredibly excited that he has now decided to join us as a member of our executive team,” added Robert W. Duggan, the Company’s Chairman and Chief Executive Officer. “Leveraging his leadership and wisdom on a daily basis is a powerful addition to the already formidable Team Summit.

公司主席兼首席执行官罗伯特·W·杜根（Robert W.Duggan）补充说：“作为董事会成员，Manmeet提供了出色的管理和指导，但我们非常高兴他现在决定加入我们作为执行团队的成员。”。“每天利用他的领导和智慧是对已经非常强大的团队峰会的有力补充。

I am grateful for the trust he has displayed in Maky, me, and our team in joining our mission full-time.”.

我感谢他在麦基，我和我们的团队全职加入我们的使命所表现出的信任。”。

Mr. Soni has over 20 years of financial and operational leadership experience and joins Summit from Reata Pharmaceuticals, Inc., where he was President, Chief Operating Officer, & Chief Financial Officer. His tenure at Reata culminated in its sale to Biogen Inc. for $7.5 billion. Prior to joining Reata, Mr.

Soni先生拥有20多年的财务和运营领导经验，并加入Reata Pharmaceuticals，Inc。的峰会，他曾担任总裁，首席运营官和首席财务官。他在Reata的任期最终以75亿美元的价格出售给Biogen Inc。在加入Reata之前，先生。

Soni was the CFO at Alnylam Pharmaceuticals, Inc. He was also the CFO at Ariad Pharmaceuticals, Inc., which was purchased by Takeda Pharmaceutical Co. Ltd. for $5.4 billion in 2017. Mr. Soni was the CFO at Pharmacyclics, Inc., which, along with the leadership of Mr. Duggan and Dr. Zanganeh, was sold to AbbVie Inc.

Soni是Alnylam Pharmaceuticals，Inc。的CFO。他也是Ariad Pharmaceuticals，Inc。的CFO，该公司于2017年以54亿美元的价格被武田制药有限公司购买。Soni先生是Pharmacyclics，Inc.的CFO，与Duggan先生和Zanganeh博士的领导一起被出售给AbbVie Inc。

for $21 billion in 2015. He serves on the Board of Directors of Pulse Biosciences, Inc. and was previously a board member at Arena Pharmaceuticals, Inc., which was later sold to Pfizer Inc. for $6.7 billion. Mr. Soni has led an array of functions including finance, manufacturing, various strategic functions including ex-US commercial strategy and business development, as well as quality, risk, and program management, amongst others.

2015年为210亿美元。他曾担任Pulse Biosciences，Inc。的董事会成员，此前曾担任Arena Pharmaceuticals，Inc。的董事会成员，后来以67亿美元的价格出售给辉瑞公司。Soni先生领导了一系列职能，包括金融，制造，各种战略职能，包括前美国商业战略和业务发展，以及质量，风险和计划管理等。

Throughout his leadership career, he has raised over $7 billion through a variety of financing and business development deals..

在他的领导生涯中，他通过各种融资和商业发展交易筹集了超过70亿美元。。

“Joining Team Summit represents a transformational opportunity to make a material difference for the better, and to improve the lives of cancer patients who face significant challenges,” added Mr. Soni. “I am passionate about the mission and goals of Summit: prioritizing the patient to bring about new advancements in oncology with patient, physician, caregiver, and societal-friendly medicines.

Soni先生补充说：“加入团队峰会代表了一个转型机会，可以为更好的环境做出实质性的改变，并改善面临重大挑战的癌症患者的生活。”。“我热衷于峰会的使命和目标：优先考虑患者，以患者，医生，护理人员和社会友好型药物为肿瘤学带来新的进步。

I am honored to get to work more closely with this exceptional team as we seek to positively impact the outlook for patients with therapies that improve both quality and duration of life.”.

我很荣幸能够与这个卓越的团队更密切地合作，因为我们试图积极影响改善生活质量和持续时间的治疗患者的前景。

In conjunction with his appointment as COO, Mr. Soni is also purchasing shares of the Company worth $5 million via a private placement. In his role as COO, Mr. Soni will be responsible for all commercial activities, finance, manufacturing, legal, information technology, and human resources.

结合他被任命为首席运营官，索尼先生还通过私人配售购买了价值500万美元的公司股份。Soni先生作为首席运营官，将负责所有商业活动，金融，制造，法律，信息技术和人力资源。

Additional Summit Leadership Appointments

额外的峰会领导任命

Today, Summit announces that, effective immediately, the following elevated appointments have been made:

今天，首脑会议宣布，立即生效的任命如下：

Dave Gancarz as Chief Business & Strategy Officer

Dave Gancarz担任首席业务和战略官员

Urte Gayko, PhD, as Chief Regulatory, Quality, & Pharmacovigilance Officer

担任首席监管，质量和药物警戒官员的Urte Gayko博士

Fong Clow, DSc, as Chief Biometrics Officer

作为首席生物识别官，DSc Fong Clow

Allen S. Yang, MD, PhD, as Chief Medical Officer

Allen S.Yang，医学博士，博士，首席医疗官

“We are very pleased with the progress we are making over the past nine months since we have completed our deal with Akeso to in-license ivonescimab,” noted Mr. Duggan. “Along with Maky, this core group of leaders that we have appointed to these new, well-earned leadership positions has led Team Summit to reach these heights.

Duggan先生指出：“自从我们完成与Akeso的交易以获得ivonescimab许可后，我们对过去九个月取得的进展非常满意。”。“与Maky一起，我们任命这些新的，高得多的领导职位的核心领导人小组已经领导团队峰会达到了这些高度。

We are well positioned to achieve our goals: growing awareness and understanding of ivonescimab in North America and Europe and timely progression of our current and planned clinical trials. Team Summit is well-positioned for the next chapter of its growth and prosperity.”.

我们有能力实现我们的目标：提高对北美和欧洲ivonescimab的认识和理解，以及及时推进我们目前和计划中的临床试验。团队峰会为其增长与繁荣的下一章做好了准备。”。

“I am extremely proud to be surrounded by such an outstanding leadership team,” added Dr. Zanganeh. “Team Summit brings a wealth of experiences that I believe sets us apart from our peers and provides us with the best opportunity for success as an organization. I would like to congratulate each of our newly elevated leaders on this well-deserved recognition, and I look forward to our expanding success as we continue to embark on our mission.”.

Zanganeh博士补充说：“我非常自豪被这样一个杰出的领导团队所包围。”。“团队峰会带来了丰富的经验，我相信这些经验使我们与同龄人脱颖而出，为我们提供了作为一个组织取得成功的最佳机会。我想祝贺我们每个新提升的领导人对这一应得的认可，我期待随着我们继续着手我们的使命，我们不断扩大的成功“。

Mr. Gancarz joined Summit in November 2020 and has held roles of increasing breadth and responsibility. Of note, Mr. Gancarz led the transaction between Summit and Akeso, Inc. to in-license the novel, potentially first-in-class bispecific antibody, ivonescimab, that has become the cornerstone of Summit’s product pipeline.

Gancarz先生于2020年11月参加了峰会，并发挥了越来越广泛和责任的作用。值得注意的是，Gancarz先生领导了Summit和Akeso，Inc.之间的交易，以许可这种新型的，可能是一流的双特异性抗体ivonescimab，它已成为Summit产品管道的基石。

Mr. Gancarz brings over 15 years of strategic leadership, operational, and financial experience. He previously held various leadership roles at Athenahealth, Inc. and PricewaterhouseCoopers LLP. Mr. Gancarz earned his undergraduate and master’s degrees at Stonehill College. As Chief Business & Strategy Officer, he is responsible for business development, corporate strategy, stakeholder relations, alliance management, program management, and medical affairs..

Gancarz先生拥有超过15年的战略领导，运营和财务经验。他以前在Athenahealth，Inc。和PricewaterhouseCoopers LLP担任过各种领导角色。Gancarz先生在斯通山学院获得本科和硕士学位。作为首席业务和战略官员，他负责业务发展，公司战略，利益相关者关系，联盟管理，计划管理和医疗事务。。

Dr. Gayko initially joined Summit as a member of the Board of Directors before transitioning from the Board into a full-time role on our leadership team in April 2022. Dr. Gayko was previously the Global Head of Regulatory Affairs and Pharmacovigilance at Pharmacyclics, as well as Senior Vice President of Drug Development & Regulatory Affairs at Nektar Therapeutics.

Gayko博士最初作为董事会成员加入峰会，然后于2022年4月从董事会过渡到我们领导团队的全职工作。Gayko博士曾担任Pharmacyclics的监管事务和药物警戒全球负责人，以及Nektar Therapeutics的药物开发和监管事务高级副总裁。

She brings over 20 years of experience in areas encompassing regulatory and clinical development ranging from pre-commercial entities to large biopharmaceutical companies, including Amgen Inc. and AbbVie Inc. Dr. Gayko led the regulatory approval process for 12 US indications for IMBRUVICA® (ibrutinib) while at Pharmacyclics.

她在从商业前实体到大型生物制药公司（包括Amgen Inc.和AbbVie Inc.）等监管和临床开发领域拥有20多年的经验.Gayko博士领导了美国12个IMBRUVICA®适应症的监管审批程序。（依鲁替尼）在Pharmacyclics。

She performed her PhD research in molecular and cellular biology at Harvard University. Dr. Gayko is responsible for regulatory affairs, quality assurance, and safety sciences in her role as Chief Regulatory, Quality, & Pharmacovigilance Officer..

她在哈佛大学进行了分子和细胞生物学博士研究。Gayko博士负责监管事务，质量保证和安全科学，担任首席监管，质量和药物警戒官员。。

Dr. Clow joined Summit in July 2021 after over a decade of leadership at Pharmacyclics and later AbbVie. Dr. Clow brings over 30 years of experience, leading extensive teams in biometrics and drug development, including leadership roles at Genentech, Inc. and Novacea, Inc. Specifically, her leadership in biometrics and drug development has contributed to 19 approvals across oncology, cardiovascular, and neurology indications.

经过十多年在Pharmacyclics和后来的AbbVie的领导，Clow博士于2021年7月加入峰会。Clow博士拥有30多年的经验，领导着生物识别和药物开发领域的广泛团队，包括Genentech，Inc。和Novacea，Inc。的领导角色。具体而言，她在生物识别和药物开发方面的领导力为肿瘤学，心血管领域的19项审批做出了贡献。和神经病学适应症。

Dr. Clow has published over 60 manuscripts and conference abstracts. She received her doctoral and master’s degrees from Harvard T.S. Chan School of Public Health, where, in 2019, she received the prestigious Lagakos Distinguished Alumni Award. In her role as Chief Biometrics Officer, Dr. Clow is responsible for all biometrics-related activities, including leading biostatistics and data management..

Clow博士发表了60多篇手稿和会议摘要。她获得了哈佛大学陈公共卫生学院的博士和硕士学位，并于2019年获得了着名的Lagakos杰出校友奖。Clow博士担任首席生物识别官员，负责所有与生物识别相关的活动，包括领先的生物统计学和数据管理。。

Dr. Yang joined Summit in July 2023, leading clinical development and research activities at Summit. Dr. Yang brings a wealth of experience in clinical oncology, immunotherapy, and bispecific antibody development through his over 20 years of combined clinical and industry experience. Dr. Yang previously served as Chief Medical Officer at Xencor, Inc.

杨博士于2023年7月加入峰会，领导峰会的临床开发和研究活动。杨博士通过20多年的临床和行业经验，在临床肿瘤学，免疫治疗和双特异性抗体开发方面拥有丰富的经验。杨博士以前曾担任Xencor，Inc。的首席医疗官。

and was the acting CMO at Jazz Pharmaceuticals PLC after serving in roles of increasing leadership responsibility starting with leading the hematology and oncology therapeutic area. Dr. Yang was previously on faculty at the University of Southern California, where he also earned his medical degree and PhD.

并且是Jazz Pharmaceuticals PLC的代理CMO，从领导血液学和肿瘤学治疗领域开始担任越来越重要的领导责任。杨博士以前曾在南加州大学任教，在那里他还获得了医学学位和博士学位。

He performed his fellowship at the University of Texas MD Anderson Cancer Center where he was Chief Fellow. Dr. Yang will continue to lead clinical development and all research-related activities in his role as Chief Medical Officer..

他在德克萨斯大学MD安德森癌症中心担任首席研究员。杨博士将继续领导临床开发和所有与研究相关的活动，担任首席医疗官。。

Summit Therapeutics’ Mission Statement

峰会治疗学的使命声明

To build a viable, long-lasting health care organization that assumes full responsibility for designing, developing, trial execution and enrollment, regulatory submission and approval, and successful commercialization of patient, physician, caregiver, and societal-friendly medicinal therapy intended to: improve quality of life, increase potential duration of life, and resolve serious medical healthcare needs.

建立一个可行，持久的医疗保健组织，全面负责设计，开发，试验执行和注册，监管提交和批准，以及患者，医生，护理人员和社会友好药物治疗的成功商业化，旨在：改善生活质量，增加潜在的生命周期，并解决严重的医疗保健需求。

To identify and control promising product candidates based on exceptional scientific development and administrational expertise, develop our products in a rapid, cost-efficient manner, and to engage commercialization and/or development partners when appropriate..

为了根据卓越的科学发展和管理专业知识确定和控制有希望的候选产品，以快速，经济高效的方式开发我们的产品，并在适当的时候聘请商业化和/或开发合作伙伴。。

We accomplish this by building a team of world class professional scientists and business administrators that apply their experience and knowledge to this mission. Team Summit exists to pose, strategize, and execute a path forward in medicinal therapeutic health care that places Summit in a well-deserved, top market share, leadership position.

我们通过建立一个由世界级专业科学家和企业管理人员组成的团队来实现这一目标，他们将自己的经验和知识应用于这一使命。团队峰会的存在是为了构成，制定战略并执行药物治疗保健方面的前进道路，使峰会处于一个应得的顶级市场份额和领导地位。

Team Summit assumes full responsibility for stimulating continuous expansion of knowledge, ability, capability, and well-being for all involved stakeholders and highly-valued shareholders..

Team Summit负全部责任，促进所有相关利益相关者和高价值股东不断扩大知识，能力，能力和福祉。。

About Ivonescimab

Ivonescimab

Ivonescimab, known as SMT112 in the United States, Canada, Europe, and Japan (Summit’s license territories), and as AK112 in China and Australia, is a novel, potential first-in-class investigational bispecific antibody combining the effects of immunotherapy via a blockade of PD-1 with the anti-angiogenesis effects associated with blocking VEGF into a single molecule.

Ivonescimab，在美国，加拿大，欧洲和日本（Summit的许可地区）被称为SMT112，在中国和澳大利亚被称为AK112，是一种新型的，潜在的一流的研究性双特异性抗体，结合了免疫疗法的效果通过阻断PD-1与将VEGF阻断成单个分子相关的抗血管生成作用。

Ivonescimab was discovered by Akeso Inc. (HKEX Code: 9926.HK) and is currently engaged in multiple Phase III clinical trials. Summit has begun its clinical development of ivonescimab in NSCLC, enrolling the first patient in its license territory in 2023, with multiple Phase III clinical trials intended to be initiated in 2023.

Ivonescimab由Akeso Inc.（HKEX代码：9926.HK）发现，目前正在进行多项III期临床试验。Summit已开始在NSCLC中开展ivonescimab的临床开发，于2023年在其许可区域招募第一名患者，并计划于2023年启动多项III期临床试验。

Over 825 patients have been treated with ivonescimab in clinical studies in China and Australia, with enrollment beginning recently in the United States..

在中国和澳大利亚的临床研究中，已有825例患者接受了ivonescimab治疗，最近在美国开始招募。。

About Summit Therapeutics

关于Summit Therapeutics

Summit was founded in 2003 and our shares are listed on the Nasdaq Global Market (symbol ‘SMMT’). We are headquartered in Menlo Park, California, and we have additional offices in Oxford, UK.

峰会成立于2003年，我们的股票在纳斯达克全球市场（符号'SMMT'）上市。我们总部设在加利福尼亚州门洛帕克，我们在英国牛津设有额外的办事处。

For more information, please visit https://www.smmttx.com and follow us on X (formerly Twitter) @summitplc.

欲了解更多信息，请访问https://www.smmttx.com然后跟随我们X（以前的Twitter）@summitplc。

Summit Forward-looking Statements

峰会前瞻性声明

Any statements in this press release about the Company’s future expectations, plans and prospects, including but not limited to, statements about the clinical and preclinical development of the Company’s product candidates, entry into and actions related to the Company’s partnership with Akeso Inc., the therapeutic potential of the Company’s product candidates, the potential commercialization of the Company’s product candidates, the timing of initiation, completion and availability of data from clinical trials, the potential submission of applications for marketing approvals, the impact of the COVID-19 pandemic on the Company’s operations and clinical trials, potential acquisitions and other statements containing the words 'anticipate,' 'believe,' 'continue,' 'could,' 'estimate,' 'expect,' 'intend,' 'may,' 'plan,' 'potential,' 'predict,' 'project,' 'should,' 'target,' 'would,' and similar expressions, constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995.

本新闻稿中有关本公司未来期望，计划和前景的任何声明，包括但不限于有关本公司产品候选人的临床和临床前发展，与Akeso Inc.合作的进入和行动相关的声明，治疗公司产品候选人的潜力，公司候选产品的潜在商业化，临床试验数据的启动，完成和可用时间，上市批准申请的潜在提交，COVID-19大流行对公司运营和临床试验的影响，潜在收购和其他包含“预期”一词的陈述，相信，“继续”，“可以”，“估计”，“期望”，“打算”，“可能”，“计划”，“潜力”，“预测”，“项目”，“应该”，“目标”，“将会”和类似的表达，构成1995年“私人证券诉讼改革法”含义内的前瞻性陈述。

Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including the results of our evaluation of the underlying data in connection with the development and commercialization activities for SMT112, the outcome of discussions with regulatory authorities, including the Food and Drug Administration, the uncertainties inherent in the initiation of future clinical trials, availability and timing of data from ongoing and future clinical trials, the results of such trials, and their success, and global public health crises, including the coronavirus COVID-19 outbreak, that may affect timing and status of our clinical trials and operations, whether preliminary results from a clinical trial .

由于各种重要因素，实际结果可能与此类前瞻性声明所表明的结果大不相同，包括我们对与SMT112开发和商业化活动有关的基础数据的评估结果，与监管机构讨论的结果，包括食品和药物管理局，未来临床试验开始时固有的不确定性，正在进行的和未来的临床试验数据的可用性和时间，这些试验的结果及其成功，以及全球公共卫生危机，包括冠状病毒COVID-19爆发，可能会影响我们临床试验和手术的时间和状态，无论是临床试验的初步结果。

* Ivonescimab is an investigational therapy that is not approved by any regulatory agency.

*Ivonescimab是一种未经任何监管机构批准的研究性治疗。